What do systematic reviews say?

Summary of findings: ACBT vs PEP mask therapy

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs OD

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs other breathing techniques

The review found no eligible studies for this question.

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: ACBT vs exercise

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Summary of findings: ACBT vs CCPT

Summary of findings: ACBT showed no clear difference in number of pulmonary exacerbations compared with CCPT (low certainty).

• Active cycle of breathing technique for cystic fibrosis 2023 · Cochrane Headline outcomes only
  RR 1.64 [0.62, 4.34]
  1 study · 63 participants
  Low

Digital technology (web‐based platform CFHealthHub) vs usual care

Digital technology (web‐based platform CFHealthHub) probably leads to lower number of pulmonary exacerbations compared with usual care (moderate certainty).

• Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  rate ratio 0.92
  1 study · 607 participants
  Moderate

Digital technology (TIM) vs standard treatment (TBM)

The review found no eligible studies for this question.

• Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Probiotics vs placebo

• Probiotics for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 225 participants
  Low

Dornase alfa vs alternate days

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  43 participants
  Low

Dornase alfa vs hypertonic saline

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  431 participants
  Low

Summary of findings: liprotamase vs porcine PERT

Summary of findings: liprotamase showed no clear difference in pulmonary exacerbations: number of exacerbations compared with porcine PERT (low certainty).

• Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  OR 0.56 [0.13, 2.45]
  1 study · 128 participants
  Low

Standard rhGH vs no treatment

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 94 participants
  Very low

High‐dose rhGH vs placebo

High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with placebo (low certainty).

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  RR 1.92 [0.66, 5.61]
  1 study · 42 participants
  Low

High‐dose rhGH vs standard‐dose rhGH

High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with standard‐dose rhGH (low certainty).

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  RR 1.28 [0.52, 3.18]
  1 study · 42 participants
  Low

Standard rhGH vs placebo

Standard rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with placebo (low certainty).

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  RR 1.5 [0.49, 4.59]
  1 study · 44 participants
  Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in pulmonary exacerbations: number of pulmonary exacerbations compared with tobramycin (moderate certainty).

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  RR 1.19 [0.86, 1.64]
  1 study · 374 participants
  Moderate

Summary of findings ‐ weekly azithromycin vs daily azithromycin

• Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 208 participants
  Moderate

Zinc vs placebo

Summary of findings: Zinc supplementation showed no clear difference in pulmonary exacerbations number of participants requiring IV… compared with placebo (moderate certainty).

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  RR 1.85 [0.65, 5.26]
  1 study · 37 participants
  Moderate

Summary of findings: tobramycin for inhalation powder vs tobramycin

Summary of findings: tobramycin for inhalation powder showed no clear difference in pulmonary exacerbations: number of participants experiencing… compared with tobramycin (moderate certainty).

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  RR 1.12 [0.86, 1.45]
  1 study · 517 participants
  Moderate

Omega‐3 vs placebo

• Omega‐3 fatty acid supplementation for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 13 participants
  Very low